[go: up one dir, main page]

NO20040511L - Aminoisoxazole derivatives as kinase inhibitors - Google Patents

Aminoisoxazole derivatives as kinase inhibitors

Info

Publication number
NO20040511L
NO20040511L NO20040511A NO20040511A NO20040511L NO 20040511 L NO20040511 L NO 20040511L NO 20040511 A NO20040511 A NO 20040511A NO 20040511 A NO20040511 A NO 20040511A NO 20040511 L NO20040511 L NO 20040511L
Authority
NO
Norway
Prior art keywords
compounds
kinase inhibitors
aminoisoxazole derivatives
aminoisoxazole
derivatives
Prior art date
Application number
NO20040511A
Other languages
Norwegian (no)
Inventor
Paolo Pevarello
Barbara Salom
Anna Vulpetti
Marcello Cavicchioli
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of NO20040511L publication Critical patent/NO20040511L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives forbindelser med formel (I) som er aminoisoksazolderivater, eller farmasøytisk akseptable salter derav, sammen med farmasøytiske preparater omfattende forbindelsene.Forbindelsene eller preparatene har anvendelse ved terapi av sykdommer forårsaket av og/eller forbundet med en endret proteinkinase-aktivitet som cancer, celleproliferative lidelser, Alzheimers sykdom, virale infeksjoner, autoimmune sykdommer og neuro-degenerative lidelser.There are described compounds of formula (I) which are aminoisoxazole derivatives, or pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising the compounds. The compounds or compositions are used in the therapy of diseases caused by and / or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, autoimmune diseases and neuro-degenerative disorders.

NO20040511A 2001-08-06 2004-02-03 Aminoisoxazole derivatives as kinase inhibitors NO20040511L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92175101A 2001-08-06 2001-08-06
PCT/EP2002/008634 WO2003013517A1 (en) 2001-08-06 2002-07-29 Aminoisoxazole derivatives active as kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20040511L true NO20040511L (en) 2004-03-23

Family

ID=25445927

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040511A NO20040511L (en) 2001-08-06 2004-02-03 Aminoisoxazole derivatives as kinase inhibitors

Country Status (18)

Country Link
US (1) US20050059657A1 (en)
EP (1) EP1435948A1 (en)
JP (1) JP2005501073A (en)
KR (1) KR20040030941A (en)
CN (1) CN1549714A (en)
AU (1) AU2002342607B2 (en)
BR (1) BR0211742A (en)
CA (1) CA2455631A1 (en)
CO (1) CO5640104A2 (en)
CZ (1) CZ2004168A3 (en)
EA (1) EA006769B1 (en)
IL (1) IL159926A0 (en)
MX (1) MXPA04000920A (en)
NO (1) NO20040511L (en)
NZ (1) NZ530782A (en)
PL (1) PL368403A1 (en)
WO (1) WO2003013517A1 (en)
ZA (1) ZA200400347B (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002785A (en) * 2001-09-24 2004-07-29 Elan Pharm Inc Substituted amines for the treatment of alzheimer's disease.
NZ619746A (en) 2003-08-06 2014-05-30 Senomyx Inc Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
US20050165031A1 (en) 2003-11-13 2005-07-28 Ambit Biosciences Corporation Urea derivatives as ABL modulators
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP2008500284A (en) 2004-05-12 2008-01-10 ブリストル−マイヤーズ　スクイブ　カンパニー P2Y1 receptor urea antagonist useful for the treatment of thrombosis
JP2008510734A (en) * 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド Kinase inhibitor
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
ATE499370T1 (en) 2005-01-19 2011-03-15 Bristol Myers Squibb Co 2-PHENOXY-N-(1,3,4-THIADIZOL-2-YL)PYRIDINE-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES
MY158077A (en) 2005-02-04 2016-08-30 Senomyx Inc Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers tastants and taste enhancers for comestible compositions
WO2006132197A1 (en) 2005-06-07 2006-12-14 Shionogi & Co., Ltd. HETEROCYCLIC COMPOUND HAVING TYPE I 11β HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY
AR055329A1 (en) 2005-06-15 2007-08-15 Senomyx Inc BIS-AROMATIC AMIDAS AND ITS USES AS SWEET FLAVORS, FLAVORS, AND FLAVOR ENHANCERS
ATE502924T1 (en) 2005-06-27 2011-04-15 Bristol Myers Squibb Co LINEAR UREA MIMETIC ANTAGONISTS OF THE P2Y1 RECEPTOR FOR THE TREATMENT OF THROMBOSIS
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
KR20080027890A (en) 2005-06-27 2008-03-28 브리스톨-마이어스 스큅 컴퍼니 N-linked heterocyclic antagonists of the P2Ｙ1 receptor useful for the treatment of thrombotic symptoms
DE602006017694D1 (en) 2005-06-27 2010-12-02 Bristol Myers Squibb Co C-LINKED CYCLIC ANTAGONISTS OF THE P2Y1 RECEPTOR SUITABLE FOR THE TREATMENT OF THROMBOTIC SUFFERING
EP1772449A1 (en) 2005-10-05 2007-04-11 Bayer CropScience S.A. New N-alkyl-heterocyclyl carboxamide derivatives
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
BRPI0617306A2 (en) * 2005-10-11 2011-07-19 Hoffmann La Roche isoxazole derivatives
ES2341131T3 (en) * 2005-11-09 2010-06-15 F.Hoffmann-La Roche Ag DERIVATIVES OF 3-ARIL-ISOXAZOL-4-CARBONIL-BENZOFURANO.
KR101394245B1 (en) 2005-12-30 2014-05-14 에스케이바이오팜 주식회사 Isoxazole Derivatives and Use thereof
WO2007114124A1 (en) 2006-03-30 2007-10-11 Shionogi & Co., Ltd. ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11β-HYDROXYSTEROID DEHYDROGENASE TYPE I
US8148536B2 (en) 2006-04-21 2012-04-03 Senomyx, Inc. Comestible compositions comprising high potency savory flavorants, and processes for producing them
CN101466691B (en) * 2006-06-08 2011-07-27 伊莱利利公司 Substituted carboxamides as group I metabotropic receptor antagonists
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010505962A (en) 2006-10-09 2010-02-25 武田薬品工業株式会社 Kinase inhibitor
WO2008046072A2 (en) * 2006-10-13 2008-04-17 The Board Of Regents Of The University Of Texas System Chemical inducers of neurogenesis
US8193225B2 (en) 2006-10-13 2012-06-05 The Board Of Regents Of The University Of Texas System Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
ES2379746T3 (en) * 2007-06-29 2012-05-03 Sk Biopharmaceuticals Co., Ltd. Pharmaceutical composition for the prevention and treatment of restenosis comprising isoxazole derivatives
CA2699157A1 (en) 2007-09-10 2009-03-19 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2009076454A2 (en) * 2007-12-12 2009-06-18 Calcimedica, Inc. Compounds that modulate intracellular calcium
KR101724161B1 (en) * 2008-08-27 2017-04-06 칼시메디카, 인크 Compounds that modulate intracellular calcium
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
US8618307B2 (en) 2009-09-16 2013-12-31 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN103242256A (en) * 2013-05-21 2013-08-14 苏州科捷生物医药有限公司 Synthetic method of 3-aminomethyl-isoxazole hydrochloride
KR101646180B1 (en) 2014-09-22 2016-08-05 한양대학교 에리카산학협력단 N-(5-arylamido-2-methylphenyl)-5-methylisooxazole-4-carboxamide deravative, pharmaceutical acceptable salt thereof, method for preparation thereof and FMS kinase inhibitor comprising the same
KR20210095143A (en) 2018-10-22 2021-07-30 어셈블리 바이오사이언시스, 인크. 5-membered heteroaryl carboxamide compounds for the treatment of HBV
EP3995494B1 (en) * 2020-11-06 2025-06-18 Eberhard Karls Universität Tübingen Protein-protein interaction modulators of aurora kinase a and their use in the prevention and/or treatment of cancer
CN113069451B (en) * 2021-04-02 2022-08-09 苏州大学 Preparation method of pyrrole-2-sulfonamide compound and application of pyrrole-2-sulfonamide compound in preparation of antitumor drugs
CN116283946B (en) * 2023-03-27 2024-05-07 武汉工程大学 5- (N-substituted indole-5-yl) isoxazole-3-formic acid derivative and synthetic method and application thereof
WO2024236054A1 (en) * 2023-05-15 2024-11-21 Stichting Amsterdam UMC Novel tracer for the in vivo detection of the aggregation of alpha-synuclein

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1108397A (en) * 1965-08-18 1968-04-03 Geigy Ag J R 5-nitro-2-furyl-isoxazoles
GB1162257A (en) * 1965-09-22 1969-08-20 Danippon Pharmaceutical Co Ltd 3-(5-Nitro-2-Furyl) Isoxazole Derivatives and methods of preparation thereof
US3631169A (en) * 1966-09-22 1971-12-28 Dainippon Pharmaceutical Co 3-(5-nitro-2-furyl)isoxazoline derivatives
US3522252A (en) * 1968-04-03 1970-07-28 R & L Molecular Research Ltd Basic esters of 5-alkanoylamino-3-(5'-nitrofur - 2' - yl)isoxazole - 4 - carboxylic acid
GB1250219A (en) * 1968-12-06 1971-10-20
US5968737A (en) * 1996-11-12 1999-10-19 The University Of Mississippi Method of identifying inhibitors of glutathione S-transferase (GST) gene expression
CZ2002534A3 (en) * 1999-08-13 2002-07-17 Vertex Pharmaceuticals Incorporated Inhibitors of protein-kinases, pharmaceutical preparations in which they are comprised as well as their use
DE60122176T2 (en) * 2000-09-15 2007-07-05 Vertex Pharmaceuticals Inc., Cambridge ISOXAZOLE AND ITS USE AS ERK INHIBITORS

Also Published As

Publication number Publication date
AU2002342607B2 (en) 2006-10-19
PL368403A1 (en) 2005-03-21
EA200400289A1 (en) 2004-06-24
BR0211742A (en) 2004-08-24
KR20040030941A (en) 2004-04-09
US20050059657A1 (en) 2005-03-17
CA2455631A1 (en) 2003-02-20
JP2005501073A (en) 2005-01-13
ZA200400347B (en) 2005-03-30
CN1549714A (en) 2004-11-24
IL159926A0 (en) 2004-06-20
EP1435948A1 (en) 2004-07-14
MXPA04000920A (en) 2004-04-02
NZ530782A (en) 2005-11-25
CO5640104A2 (en) 2006-05-31
EA006769B1 (en) 2006-04-28
CZ2004168A3 (en) 2004-05-12
WO2003013517A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
NO20040511L (en) Aminoisoxazole derivatives as kinase inhibitors
DK1427708T3 (en) Amino-phthalazinone derivatives such as kinase inhibitors, processes for their preparation, and pharmaceutical compositions containing the same
NO20041086L (en) Aminoindazole derivatives active as kinase inhibitors, processes for their preparation, and pharmaceutical compositions containing them
DK1377589T3 (en) Oxazolyl-pyrazole derivatives as kinase inhibitors
MXPA02012164A (en) Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
NO20055496L (en) Pyrazoloquinazoline derivatives, methods for their preparation and their use as kinase inhibitors
MXPA05009719A (en) Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
CA2486101A1 (en) Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2003218989A1 (en) Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
DE602004017194D1 (en) PYRIDYLPYRROL DERIVATIVES AS ACTIVE KINASE INHIBITORS
NO20030381L (en) Bicyclopyrazoles which are active as kinase inhibitors, processes for their preparation and pharmaceutical preparations containing such compounds
NO20021328L (en) Pyrazolopyrimidia as therapeutic agents
BR0312722A (en) Heterobicylic pyrazole derivatives as kinase inhibitors
BR0314797A (en) Pyrimidineamide derivatives and their use
DE602004014163D1 (en) PYRIMIDYLPYRROL DERIVATIVES ACTING AS KINASEINHIBITORS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application